EQL Pharma Dirección

Dirección controles de criterios 3/4

El CEO de EQL Pharma es Axel Schorling , nombrado en Aug 2022, tiene una permanencia de 2.25 años. compensación anual total es SEK2.26M, compuesta por 72.6% salario y 27.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.07% de las acciones de la empresa, por valor de SEK19.59M. La antigüedad media del equipo directivo y de la junta directiva es de 2.3 años y 4.8 años, respectivamente.

Información clave

Axel Schorling

Chief Executive Officer (CEO)

SEK 2.3m

Compensación total

Porcentaje del salario del CEO	72.6%
Permanencia del CEO	2.3yrs
Participación del CEO	1.1%
Permanencia media de la dirección	2.3yrs
Promedio de permanencia en la Junta Directiva	4.8yrs

Actualizaciones recientes de la dirección

Recent updates

Market Participants Recognise EQL Pharma AB (publ)'s (STO:EQL) Earnings Pushing Shares 26% Higher

Oct 29

EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings

Aug 22

Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden

Aug 12

EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce

Jun 13

EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price

May 14

EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

Feb 21

How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?

Mar 11

Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Feb 21

Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Feb 03

What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation

Jan 16

Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?

Dec 28

What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?

Dec 11

EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment

Nov 22

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Axel Schorling en comparación con los beneficios de EQL Pharma?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	SEK 31m
Jun 30 2024	n/a	n/a	SEK 26m
Mar 31 2024	SEK 2m	SEK 2m	SEK 23m

Compensación vs. Mercado: La compensación total de Axel($USD207.12K) está por debajo de la media de empresas de tamaño similar en el mercado Swedish ($USD455.00K).

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Axel con los resultados de la empresa.

CEO

Axel Schorling (38 yo)

2.3yrs

Permanencia

SEK 2,262,000

Compensación

Mr. Axel Schorling has been Independent Director at Gasporox AB (publ) since 2023. Mr. Schörling is President of EQL Pharma AB (publ) from August 15, 2022. He had been the Chief Operating Officer of EQL Ph...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Christer Fahraeus	Founder & Chairman	18.8yrs	SEK 250.00k	sin datos
Axel Schorling	President & CEO	2.3yrs	SEK 2.26m	1.07% SEK 19.6m
Anna Jonsson	Chief Financial Officer	2.9yrs	sin datos	0.047% SEK 865.0k
Martin Kristofferson	Chief Operating Officer	2.3yrs	sin datos	0.070% SEK 1.3m
Alexander Brising	Chief Commercial Officer	no data	sin datos	0.88% SEK 16.2m
Carl Lindgren	Chief Business Development Officer	1.7yrs	sin datos	sin datos

2.3yrs

Permanencia media

50yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de EQL se considera experimentado (2.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Christer Fahraeus	Founder & Chairman	18.8yrs	SEK 250.00k	sin datos
Linda Neckmar	Independent Director	4.8yrs	SEK 100.00k	0.0086% SEK 157.5k
Anders Mansson	Independent Director	6.3yrs	SEK 100.00k	0.034% SEK 630.0k
Per Svangren	Independent Director	3.8yrs	SEK 100.00k	0.034% SEK 630.0k
Per Ollermark	Independent Director	3.8yrs	SEK 100.00k	sin datos

4.8yrs

Permanencia media

57yo

Promedio de edad

Junta con experiencia: La junta directiva de EQL se considera experimentada (4.8 años de antigüedad promedio).

EQL Pharma Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Chief Operating Officer recently bought kr281k worth of stock

EQL Pharma AB (publ) Appoints Nikunj A. Shah as New Board Member

EQL Pharma AB (publ), Annual General Meeting, Aug 19, 2024

Insufficient new directors

EQL Pharma AB (publ), Annual General Meeting, Aug 17, 2023

Founder & Chairman recently sold kr11m worth of stock

Recent updates

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Market Participants Recognise EQL Pharma AB (publ)'s (STO:EQL) Earnings Pushing Shares 26% Higher

Chief Operating Officer recently bought kr281k worth of stock

EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings

EQL Pharma AB (publ) Appoints Nikunj A. Shah as New Board Member

EQL Pharma AB (publ) to Report Fiscal Year 2025 Results on May 08, 2025

Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden

First quarter 2025 earnings: Revenues exceed analyst expectations

EQL Pharma AB (publ), Annual General Meeting, Aug 19, 2024

EQL Pharma AB's Key Product Mellozzan[® ](melatonin) Receives Marketing Approval in Switzerland

EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce

Investor sentiment improves as stock rises 16%

Full year 2024 earnings: EPS and revenues miss analyst expectations

Eql Pharma AB (Publ) Provides Sales Guidance for the Year 2024/25

EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price

EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture

Third quarter 2024 earnings released

Insufficient new directors

Second quarter 2024 earnings released: EPS: kr0.16 (vs kr0.26 in 2Q 2023)

EQL Pharma AB (publ) to Report Fiscal Year 2024 Results on May 14, 2024

New major risk - Earnings quality

Full year 2023 earnings released: EPS: kr1.06 (vs kr1.09 in FY 2022)

EQL Pharma AB (publ) to Report Q1, 2024 Results on Aug 16, 2023

EQL Pharma AB (publ), Annual General Meeting, Aug 17, 2023

The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested

Full year 2023 earnings released: EPS: kr1.06 (vs kr1.09 in FY 2022)

With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case

Founder & Chairman recently sold kr11m worth of stock

EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors

Investor sentiment improves as stock rises 18%

Third quarter 2023 earnings released

EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital

Second quarter 2023 earnings released: EPS: kr0.26 (vs kr0.18 in 2Q 2022)

EQL Pharma AB (publ) Launches One-Step "Lollipop" Antigen Self-Test for Covid-19 in the Nordics - All in One - One Device, One Step

First quarter 2023 earnings released

EQL Pharma AB (publ) Announces Executive Changes

EQL Pharma AB (publ) to Report Q3, 2023 Results on Feb 14, 2023

Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?

Full year 2022 earnings released: EPS: kr1.09 (vs kr0.36 in FY 2021)

EQL Pharma Receives Approval of Glycopyrronium EQL Pharma Solution for Injection 0.2Mg/Ml from Danish Medicines Agency

Is EQL Pharma (NGM:EQL) Using Too Much Debt?

EQL Pharma AB (publ) to Report Fiscal Year 2022 Results on May 13, 2022

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2022 earnings released

We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair

Full year 2021 earnings released: EPS kr0.36 (vs kr0.09 in FY 2020)

EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns

Investor sentiment improved over the past week

If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late

How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?

EQL Pharma AB (Publ) Announces Approval of Mellozzan (Melatonin)

Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Third quarter 2021 earnings released

EQL Pharma AB (Publ) Convenes Nomination Committee

EQL Pharma Announces Approval of Glucosparc (Metformin)

Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

New 90-day high: kr40.00

What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation

Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day high: kr33.50

What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?

Director recently sold kr285k worth of stock

EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment

EQL Pharma Receives a New Order for Consumables from a Hospital Region

Director recently sold kr2.8m worth of stock

Market bids up stock over the past week

Market pulls back on stock over the past week